Determining the role of NLRP3 on the placement and protective potential of CD73+ BRMs post influenza infection

确定 NLRP3 对流感感染后 CD73 BRM 的放置和保护潜力的作用

基本信息

项目摘要

Project Summary Little is known about antigen (Ag) specific memory B (BMEM) cells, in the context of a public health relevant pathogen. Our studies clearly resolve the subsets of non-circulating, influenza specific, resident memory B cells (BRM) in the lung. BRM establishment relied on early CD40 signaling and maintained a CD73 (ectoenzyme)+ and CD73- population, whereas the lymph node (LN) showed a decline in the CD73- population. This raised the question of the inherent differences in formation and function of CD73+ and CD73- BRMs. CD73 is a marker of germinal center (GC) emigrants in the LN and memory cells in the LN reside in niches close to macrophages that capture and transfer antigen and T cells which can provide help; therefore, we hypothesized that the CD73+BRMs will home to areas of organized lymphoid structures in the lung and be dependent on T cell help. Our RNASeq data shows NLRP3 (NOD-like receptor protein 3), an innate danger sensing complex, to be the most upregulated gene in CD73+BRMs. To our knowledge NLRP3 activity is not associated with B cell differentiation, which makes this finding novel and may inaugurate studies into innate like functions in B cells during adaptive responses. NLRP3 activity produces interleukin B (IL-1B) and IL-1B is a well-known up regulator of interleukin 6 (IL-6), which promotes GCs and plasma cell differentiation. As our CD73+BRMs may have higher NLRP3 expression, we hypothesize that NLRP3 will be active during recall and produce GCs and ASCs, while the CD73-BRMs may be sentinels in the lung which spontaneously convert to ASCs, in response to the returning virus. To test these hypotheses, we ask the following: 1) Are CD73+ and CD73- BRM cells dependent on GCs? If so, GC-specific blockade should reduce CD73+ BRMs in the lung and produce low affinity BCRs. 2) Do CD73+ BRMs preferentially reside in iBALT? If so, using histology, we should observe them congregating in the iBALT while the CD73-BRMs are scattered in the parenchyma. 3) Do CD73+ and CD73- BRM cells respond differently in functional assays? We will answer this question by performing in vitro assays for BRM differentiation to ASCs, using cytokine cocktails and sorted T cells. 4) Does the NLRP3 complex become activated in BRMs upon viral challenge? If so, using NLRP3 inflammasome reporter mice, we expect that CD73+ BRM cells, but not CD73- BRM cells to increase NLRP3 activity. 5) Does NLRP3 regulate the formation or function of BRMs? If so, B cell specific NLRP3 deficiency should alter the proportions of CD73+ and CD73-BRMs and their protective function with observable differences in morbidity and mortality. The findings from this study despite the outcome will be extremely important to allow for the resolution of a target population and potential molecular targets for an effective vaccine design.
项目摘要 在与公共卫生相关的背景下,对抗原(Ag)特异性记忆B(BMEM)细胞知之甚少 病原体。我们的研究清楚地解析了非循环、流感特异性、居民记忆B的子集 肺中的细胞(BRM)。BRM的建立依赖于早期的CD40信号,并维持CD73 (胞外酶)+和CD73-群体,而淋巴结(LN)CD73- 人口。这就提出了CD73+和CD73在形成和功能上的内在差异的问题- BRMS。CD73是LN中生发中心(GC)迁移的标志,LN中的记忆细胞驻留在 靠近巨噬细胞捕获和转移抗原的壁龛,以及可以提供帮助的T细胞;因此, 我们假设CD73+BRM将是肺中有组织的淋巴结构区域的归宿,并 依赖T细胞的帮助。我们的RNAseq数据显示NLRP3(节点样受体蛋白3)是一种先天危险 感觉复合体,可能是CD73+BRM中表达最高的基因。据我们所知,NLRP3活动不是 与B细胞分化有关,这使得这一发现具有新颖性,并可能开启对先天 B细胞在适应性反应中的类似功能。NLRP3活性产生白介素B(IL-1B),而IL-1B 一种众所周知的白介素6(IL-6)的上调调节剂,可促进GC和浆细胞分化。作为我们的 CD73+BRM可能有较高的NLRP3表达,我们假设NLRP3在回忆和 产生GC和ASCs,而CD73-BRM可能是肺中的哨兵,自发地转化为 ASCs,作为对返回的病毒的响应。 为了验证这些假设,我们问了以下问题:1)CD73+和CD73-BRM细胞依赖于GC吗?如果 因此,GC特异性阻断应该会减少肺中CD73+BRM,并产生低亲和力的BCR。2)做CD73+ BRMS优先驻留在iBALT?如果是这样的话,利用组织学,我们应该观察到它们聚集在 CD73-BRM散在分布于实质内。3)CD73+和CD73-BRM细胞是否有反应 在功能分析上有什么不同?我们将通过对BRM进行体外检测来回答这个问题 使用细胞因子鸡尾酒和分选的T细胞向ASCs分化。4)NLRP3复合体是否会变成 在病毒挑战时在BRMS中被激活?如果是这样的话,使用NLRP3炎症报告小鼠,我们预计 CD73+BRM细胞,而不是CD73-BRM细胞增加NLRP3活性。5)NLRP3是否调节 BRM的形成或功能?如果是这样的话,B细胞特异性NLRP3缺陷应该会改变 CD73+和CD73-BRM及其保护功能在发病率和死亡率方面有明显差异。 不管结果如何,这项研究的结果将对解决 有效疫苗设计的目标人群和潜在的分子目标。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

S Rameeza Allie其他文献

S Rameeza Allie的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('S Rameeza Allie', 18)}}的其他基金

Establishment and metabolic control of influenza-specific lung-resident memory B cells
流感特异性肺驻留记忆 B 细胞的建立和代谢控制
  • 批准号:
    8982505
  • 财政年份:
    2015
  • 资助金额:
    $ 20.27万
  • 项目类别:
Establishment and metabolic control of influenza-specific lung-resident memory B cells
流感特异性肺驻留记忆 B 细胞的建立和代谢控制
  • 批准号:
    9120660
  • 财政年份:
    2015
  • 资助金额:
    $ 20.27万
  • 项目类别:

相似海外基金

Multidimensional development of high-affinity anti-glycan antibodies to fight deadly bacterial infections
多维开发高亲和力抗聚糖抗体以对抗致命细菌感染
  • 批准号:
    10549640
  • 财政年份:
    2023
  • 资助金额:
    $ 20.27万
  • 项目类别:
Computational modelling and simulation of antibodies to enhance binding affinity of a potential Burkholderia pseudomallei therapeutic
抗体的计算模型和模拟,以增强潜在的鼻疽伯克霍尔德氏菌治疗剂的结合亲和力
  • 批准号:
    2750554
  • 财政年份:
    2021
  • 资助金额:
    $ 20.27万
  • 项目类别:
    Studentship
Affinity Biosensors for COVID-19 Antibodies
适用于 COVID-19 抗体的亲和生物传感器
  • 批准号:
    61319
  • 财政年份:
    2020
  • 资助金额:
    $ 20.27万
  • 项目类别:
    Feasibility Studies
Directed Evolution of HIV Broadly Neutralizing Antibodies Using a Novel CRISPR-Engineered B cell in Vitro Affinity Maturation Platform
使用新型 CRISPR 工程 B 细胞在体外亲和力成熟平台定向进化 HIV 广泛中和抗体
  • 批准号:
    10013588
  • 财政年份:
    2020
  • 资助金额:
    $ 20.27万
  • 项目类别:
Affinity maturation and property changes of single-domain antibodies through repeated immunizations.
通过重复免疫,单域抗体的亲和力成熟和性质变化。
  • 批准号:
    20K07009
  • 财政年份:
    2020
  • 资助金额:
    $ 20.27万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Rapid structure-based software to enhance antibody affinity and developability for high-throughput screening: Aiming toward total in silico design of antibodies
基于快速结构的软件可增强抗体亲和力和高通量筛选的可开发性:旨在实现抗体的全面计算机设计
  • 批准号:
    10603473
  • 财政年份:
    2020
  • 资助金额:
    $ 20.27万
  • 项目类别:
IN SILICO DESIGN OF HIGH-AFFINITY RECOMBINANT ANTIBODIES
高亲和力重组抗体的计算机模拟设计
  • 批准号:
    2342674
  • 财政年份:
    2020
  • 资助金额:
    $ 20.27万
  • 项目类别:
    Studentship
Strategies for generating high affinity antibodies against Gram negative bacteria
产生针对革兰氏阴性菌的高亲和力抗体的策略
  • 批准号:
    10117194
  • 财政年份:
    2020
  • 资助金额:
    $ 20.27万
  • 项目类别:
Directed Evolution of HIV Broadly Neutralizing Antibodies Using a Novel CRISPR-Engineered B cell in Vitro Affinity Maturation Platform
使用新型 CRISPR 工程 B 细胞在体外亲和力成熟平台定向进化 HIV 广泛中和抗体
  • 批准号:
    10115604
  • 财政年份:
    2020
  • 资助金额:
    $ 20.27万
  • 项目类别:
Interdisciplinary protein engineering approach to design high affinity antibodies for flaviviruses
跨学科蛋白质工程方法设计黄病毒高亲和力抗体
  • 批准号:
    10294224
  • 财政年份:
    2018
  • 资助金额:
    $ 20.27万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了